An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Trial Profile

An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Jul 2017

At a glance

  • Drugs Lenvatinib (Primary)
  • Indications Thyroid cancer
  • Focus Therapeutic Use
  • Sponsors Eisai Inc
  • Most Recent Events

    • 21 Oct 2016 Planned End Date changed from 1 May 2018 to 1 Feb 2019.
    • 21 Oct 2016 Planned primary completion date changed from 1 Feb 2018 to 1 Jul 2018.
    • 21 Sep 2016 According to an Eisai Inc. media release, highlights of this trial will be presented at the 86th Annual Meeting of the American Thyroid Association (ATA) 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top